Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

NCT07220642 · Active, not recruiting

Last updated 2026-05-28

This clinical trial tested the effect of a medication called cagrilintide on weight loss in adults who are overweight or have obesity.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 300 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-11 · est. completion 2027-06

Where 40 sites · Argentina, Australia, Canada, France, Germany, Italy, Norway, Poland, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT07220642 ↗

Description as written by the study sponsor.

This study will look at how much cagrilintide helps people with overweight or obesity lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participants will either get cagrilintide or placebo. Which treatment participants get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. Possible side effects will be followed carefully during the study. For each participant, the study will last for about 1 year and 6 months.

Treatments tested

Cagrilintide Drug

Cagrilintide will be administered subcutaneously with a pen-injector as an adjunt to lifestyle intervention counselling.
Placebo Drug

Placebo matched to cagrilintide will be administered subcutaneously with a pen-injector as an adjunt to lifestyle intervention counselling.

Main thing measured	Relative change in body weight
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity, Overweight
GLP-1 drugs	cagrilintide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07220642 ↗